Evaxion Biotech A/S (EVAX)

NASDAQ: EVAX · IEX Real-Time Price · USD
3.025
+0.025 (0.83%)
Mar 28, 2024, 11:18 AM EDT - Market open

Company Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.

The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.

Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.

Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Evaxion Biotech A/S
Evaxion Biotech logo
Country Denmark
Founded 2008
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 63
CEO Christian Kanstrup M.Sc.

Contact Details

Address:
Dr Neergaards Vej 5f
Hoersholm, G7 2970
Denmark
Phone 004531262615
Website evaxion-biotech.com

Stock Details

Ticker Symbol EVAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001828253
CUSIP Number 29970R105
ISIN Number US29970R2040
SIC Code 2836

Key Executives

Name Position
Christian Kanstrup M.Sc. Chief Executive Officer
Andreas Holm Mattsson Co-Founder and Chief AI and Culture Officer
Dr. Niels Iversen Moller M.D. Co-Founder, Vice President of Business and Director
Jesper Nyegaard Nissen M.Sc. Chief Financial Officer and Chief Operating Officer
Dr. Birgitte Rono Ph.D. Chief Scientific Officer
Dr. Jürgen Langhärig EMBA, Ph.D. Head of Business Development and Member of Advisory Board

Latest SEC Filings

Date Type Title
Mar 27, 2024 6-K Report of foreign issuer
Mar 26, 2024 20-F Annual and transition report of foreign private issuers
Mar 19, 2024 6-K Report of foreign issuer
Mar 13, 2024 6-K Report of foreign issuer
Feb 29, 2024 6-K Report of foreign issuer
Feb 20, 2024 6-K Report of foreign issuer
Feb 7, 2024 6-K Report of foreign issuer
Feb 7, 2024 6-K Report of foreign issuer
Feb 6, 2024 6-K Report of foreign issuer
Feb 5, 2024 424B4 Prospectus